Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
Identifieur interne : 000114 ( PubMed/Corpus ); précédent : 000113; suivant : 000115Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
Auteurs : C. Laurencin ; T. Danaila ; E. Broussolle ; S. ThoboisSource :
- Revue neurologique [ 0035-3787 ]
Abstract
In 2000, a French consensus conference proposed guidelines for the treatment of Parkinson's disease (PD). Since then, new drugs have been concocted, new studies have been published and clinicians have become aware of some drug-induced adverse effects that were little known in the past. This has led us to reconsider the recommendations published 16 years ago. Thus, the aim of the present review is to present the recent data related to the different medications and non-pharmacological approaches available for PD, with a special focus on early-stage PD. Levodopa (LD), dopamine agonists (DAs), catechol-O-methyltransferase inhibitors (COMT-Is), anticholinergics, monoamine oxidase inhibitors (MAOB-Is) and amantadine have been considered, and their efficacy and safety for both motor as well as non-motor aspects are reported here. This has led to our proposal for a revised therapeutic strategy for the initiation of treatment in newly diagnosed PD patients, based on the available literature and the relative benefits/side effects balance.
DOI: 10.1016/j.neurol.2016.07.007
PubMed: 27476416
Links to Exploration step
pubmed:27476416Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.</title><author><name sortKey="Laurencin, C" sort="Laurencin, C" uniqKey="Laurencin C" first="C" last="Laurencin">C. Laurencin</name><affiliation><nlm:affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France. Electronic address: chloe.laurencin@chu-lyon.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Danaila, T" sort="Danaila, T" uniqKey="Danaila T" first="T" last="Danaila">T. Danaila</name><affiliation><nlm:affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France.</nlm:affiliation></affiliation></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name><affiliation><nlm:affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, 69500 Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Thobois, S" sort="Thobois, S" uniqKey="Thobois S" first="S" last="Thobois">S. Thobois</name><affiliation><nlm:affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, 69500 Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2016 Aug - Sep</MedlineDate></PubDate></date><idno type="RBID">pubmed:27476416</idno><idno type="pmid">27476416</idno><idno type="doi">10.1016/j.neurol.2016.07.007</idno><idno type="wicri:Area/PubMed/Corpus">000114</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000114</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.</title><author><name sortKey="Laurencin, C" sort="Laurencin, C" uniqKey="Laurencin C" first="C" last="Laurencin">C. Laurencin</name><affiliation><nlm:affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France. Electronic address: chloe.laurencin@chu-lyon.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Danaila, T" sort="Danaila, T" uniqKey="Danaila T" first="T" last="Danaila">T. Danaila</name><affiliation><nlm:affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France.</nlm:affiliation></affiliation></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name><affiliation><nlm:affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, 69500 Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Thobois, S" sort="Thobois, S" uniqKey="Thobois S" first="S" last="Thobois">S. Thobois</name><affiliation><nlm:affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, 69500 Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In 2000, a French consensus conference proposed guidelines for the treatment of Parkinson's disease (PD). Since then, new drugs have been concocted, new studies have been published and clinicians have become aware of some drug-induced adverse effects that were little known in the past. This has led us to reconsider the recommendations published 16 years ago. Thus, the aim of the present review is to present the recent data related to the different medications and non-pharmacological approaches available for PD, with a special focus on early-stage PD. Levodopa (LD), dopamine agonists (DAs), catechol-O-methyltransferase inhibitors (COMT-Is), anticholinergics, monoamine oxidase inhibitors (MAOB-Is) and amantadine have been considered, and their efficacy and safety for both motor as well as non-motor aspects are reported here. This has led to our proposal for a revised therapeutic strategy for the initiation of treatment in newly diagnosed PD patients, based on the available literature and the relative benefits/side effects balance.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27476416</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>01</Day></DateCreated><DateRevised><Year>2016</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><Issue>8-9</Issue><PubDate><MedlineDate>2016 Aug - Sep</MedlineDate></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.</ArticleTitle><Pagination><MedlinePgn>512-523</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0035-3787(16)30039-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2016.07.007</ELocationID><Abstract><AbstractText NlmCategory="UNASSIGNED">In 2000, a French consensus conference proposed guidelines for the treatment of Parkinson's disease (PD). Since then, new drugs have been concocted, new studies have been published and clinicians have become aware of some drug-induced adverse effects that were little known in the past. This has led us to reconsider the recommendations published 16 years ago. Thus, the aim of the present review is to present the recent data related to the different medications and non-pharmacological approaches available for PD, with a special focus on early-stage PD. Levodopa (LD), dopamine agonists (DAs), catechol-O-methyltransferase inhibitors (COMT-Is), anticholinergics, monoamine oxidase inhibitors (MAOB-Is) and amantadine have been considered, and their efficacy and safety for both motor as well as non-motor aspects are reported here. This has led to our proposal for a revised therapeutic strategy for the initiation of treatment in newly diagnosed PD patients, based on the available literature and the relative benefits/side effects balance.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laurencin</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France. Electronic address: chloe.laurencin@chu-lyon.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danaila</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broussolle</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, 69500 Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thobois</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, 69500 Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amantadine</Keyword><Keyword MajorTopicYN="N">Anticholinergics</Keyword><Keyword MajorTopicYN="N">Cathecol-O-methyltransferase inhibitors</Keyword><Keyword MajorTopicYN="N">Dopamine agonist</Keyword><Keyword MajorTopicYN="N">Levodopa</Keyword><Keyword MajorTopicYN="N">Monoamine oxidase B inhibitors</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27476416</ArticleId><ArticleId IdType="pii">S0035-3787(16)30039-X</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2016.07.007</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000114 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000114 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27476416
|texte= Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27476416" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |